Research contextSee what supports this page, how current it is, and where comparable or historical context is available.
- Research date
- Sep 21, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
- Operating-model context
- 16 connected conceptsPart of the reviewed Biopharma Development and Commercialization; issuer definitions remain distinct where disclosed.
- Company examples
- 1 reviewed companyRelationships reflect supported examples, not a normalized cross-company KPI ranking.
A PDUFA date is the target action date associated with FDA review of a qualifying drug or biologic application under Prescription Drug User Fee Act performance goals.
Why investors track it
The date can concentrate regulatory-event risk because FDA may act on an NDA or BLA around the target date.
Possible outcomes include approval, a complete response letter, or a change in timing.
Target does not mean guaranteed
A PDUFA date is not a guaranteed approval date.
MannKind's 2025 filing disclosed PDUFA target action dates for both an sBLA and an sNDA. Other issuers have also disclosed review extensions when additional information changed the review timeline.
Sources:
A PDUFA date is a regulatory review target, not a prediction of approval.
Part of the Biopharma Development and Commercialization
Connect clinical-trial evidence, FDA application and expedited pathways, collaboration economics, gross-to-net commercialization, and loss-of-exclusivity risk to understand drug-development businesses.
How the model fits together
- Clinical evidence and execution: Trial phase frames development maturity, enrollment affects execution timing, primary and secondary endpoints define the prespecified evidence hierarchy, and a readout converts that study design into new evidence for investors to interpret.
- FDA pathway and review milestones: NDA and BLA submissions begin formal marketing review for drugs and biologics, PDUFA dates frame target action timing, and accelerated approval, Breakthrough Therapy, and Orphan Drug designations describe distinct regulatory pathways or incentives rather than approval outcomes.
- Commercialization, partnerships, and exclusivity: Gross-to-net adjustments bridge gross product demand to recognized revenue, royalties and milestones describe partner economics, and patent expiry plus loss of exclusivity frame when legal protection may translate into competitive revenue erosion.
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare stocks
Compare biopharma stocks
Continue into stock comparison for pipeline stage, regulatory milestones, commercialization economics, concentration, and valuation context.
Explore more topics in the Financial Research Encyclopedia.